The P2Y12 receptor as a target of antithrombotic drugs

Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7

(2011) Johanne Silvain et al.   Circulation-Cardiovascular Interventions

Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention

(2011) Matthew J. Price   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

(2010) Sergio Leonardi et al.   AMERICAN HEART JOURNAL

Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: Rationale and design of the Assessment with a double Randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and Clopidogrel after DES implantation, and (2) Treatment Interruption versus Continuation, 1 year after stenting (ARCTIC) study

(2010) Jean-Philippe Collet et al.   AMERICAN HEART JOURNAL

The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects

(2010) M. Cattaneo   BLOOD

Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function

(2010) Stefan James et al.   CIRCULATION

Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention

(2010) Philippe Gabriel Steg et al.   CIRCULATION

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies

(2010) D J Angiolillo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

New P2Y12Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention

(2010) Anne Bellemain-Appaix et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration

(2010) Jean-Sébastien Hulot et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

(2010) Shamir R Mehta et al.   LANCET

Clopidogrel with or without Omeprazole in Coronary Artery Disease

(2010) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clopidogrel non-responsiveness and risk of cardiovascular morbidity

(2010) Rossella Marcucci et al.   THROMBOSIS AND HAEMOSTASIS

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial

(2009) Jeffrey S. Berger et al.   AMERICAN HEART JOURNAL

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update)

(2009) Frederick G. Kushner et al.   CIRCULATION

Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention

(2009) Elizabeth M. Mahoney et al.   CIRCULATION

Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

(2009) M. Kazui et al.   DRUG METABOLISM AND DISPOSITION

Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis

(2009) Dirk Sibbing et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

(2009) Gilles Montalescot et al.   LANCET

Intravenous Platelet Blockade with Cangrelor during PCI

(2009) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platelet Inhibition with Cangrelor in Patients Undergoing PCI

(2009) Robert A. Harrington et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis

(2009) J.J.J. van Giezen et al.   THROMBOSIS RESEARCH

The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance

(2008) KA Kim et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention

(2008) Dean J. Kereiakes et al.   JACC-Cardiovascular Interventions

Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance

(2008) Laurent Bonello et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY